Latest filing published 14 May 2024 for Akebia Therapeutics, Inc., €41k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Michel Dahan: trading record in brief
This profile gathers the share dealings of Michel Dahan in Akebia Therapeutics, Inc., where the filings describe the role as chief executive. Between 4 April 2016 and 13 May 2024, the trades on record add up to 37 filings.
On the market, this insider has only sold: 25 sales, €590k in total. Outside the open market, there are 11 share grants. 2024 to date brings no purchases and 3 sales.
On 14 May 2024 came the latest disclosure, an open-market sale for €41k in Akebia Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Michel Dahan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 34,840 shares@ US$1.2642.6% of flowCommon StockSEC:0001562180-24-004025:0
- 8,661 shares@ US$1.5813.2% of flowCommon StockSEC:0001562180-24-002023:0
- 10,744 shares@ US$1.5215.8% of flowCommon StockSEC:0001562180-24-001994:0
- 149,300 shares0Common StockSEC:0001562180-24-000978:0
- 200,000 shares0Common StockSEC:0001562180-23-004503:0
- 200,000 shares0Common StockSEC:0001562180-23-004168:0
- 8,058 shares@ US$0.87757.0% of flowCommon StockSEC:0001562180-23-002198:0
- 10,090 shares@ US$0.81328.1% of flowCommon StockSEC:0001562180-23-002039:0
- 6,555 shares@ US$2.154813.2% of flowCommon StockSEC:0001562180-22-002163:0
9 of 9 declarations
